🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 13 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
06/01/2023 18,64 18,72 18,09 18,48 -0,54% 3,38% 2.152.200
05/01/2023 20,11 20,57 18,00 18,58 -8,88% 12,78% 3.708.100
04/01/2023 20,43 20,70 20,05 20,39 +0,94% 3,18% 526.100
03/01/2023 20,79 21,37 19,90 20,20 -2,32% 7,05% 744.900
30/12/2022 19,89 20,79 19,89 20,68 +2,12% 4,52% 854.600
29/12/2022 20,01 20,94 19,62 20,25 +2,79% 6,60% 1.033.100
28/12/2022 20,42 20,86 19,31 19,70 -2,72% 7,59% 999.300
27/12/2022 20,30 20,47 19,80 20,25 -0,78% 3,30% 1.071.300
23/12/2022 21,46 21,66 20,39 20,41 -4,54% 5,92% 830.700
22/12/2022 21,65 21,65 20,71 21,38 -3,48% 4,36% 1.345.500
21/12/2022 20,51 22,79 20,51 22,15 +7,58% 11,12% 2.482.500
20/12/2022 24,05 24,05 20,15 20,59 -32,51% 16,20% 4.981.600
19/12/2022 30,65 31,14 28,26 30,51 -1,23% 9,38% 1.328.500
16/12/2022 30,60 31,59 30,03 30,89 -0,35% 5,11% 3.325.900
15/12/2022 33,25 33,25 30,80 31,00 -7,79% 7,37% 1.172.500
14/12/2022 33,13 34,93 32,65 33,62 +1,57% 6,88% 1.768.600
13/12/2022 32,09 33,11 31,18 33,10 +5,45% 6,01% 1.447.100
12/12/2022 30,29 31,90 29,71 31,39 +3,29% 7,23% 1.104.000
09/12/2022 30,73 31,31 30,37 30,39 -1,97% 3,06% 581.000
08/12/2022 31,87 31,87 30,04 31,00 -1,40% 5,74% 826.200
07/12/2022 31,50 32,15 31,02 31,44 -1,26% 3,58% 783.600
06/12/2022 33,90 33,90 31,69 31,84 -6,24% 6,52% 1.069.900
05/12/2022 35,50 35,50 33,35 33,96 -4,90% 6,06% 1.445.900
02/12/2022 34,12 36,13 33,81 35,71 +3,63% 6,80% 963.700
01/12/2022 34,97 35,70 33,48 34,46 -2,02% 6,35% 1.230.200
30/11/2022 31,71 35,62 30,85 35,17 +15,27% 15,04% 2.356.100
29/11/2022 28,98 31,99 28,71 30,51 +6,57% 11,32% 1.289.100
28/11/2022 29,31 30,32 27,57 28,63 +7,19% 9,38% 1.820.500
25/11/2022 26,84 27,24 26,44 26,71 -1,69% 2,98% 204.500
23/11/2022 26,86 27,33 26,37 27,17 +0,00% 3,59% 428.200